Jump to content [Access key 'm'] Jump to site navigation [Access key 'n'] Jump to Contact Us and Glossary [Access key 's'] Jump to Site Services and Sitemap [Access key 's'] Jump to local navigation [Access key 'l']
 

Our Company

We are a diversified biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Our strategy is focused on leading edge therapeutic management of cancer patients based on a portfolio of three medicines marketed by our ALIGN subsidiary and a deep development pipeline.

Our Strategy

We are focused on the discovery and development of orally-available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors, and enhancing the quality of life and improving survival rates of cancer patients.

Read more about our Business Strategy

Our People

Board of directors
Management team
Scientific advisory board

Read more about our People

Our History

We were founded in 1996 by Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein.

Read more about our Company Overview

Go to top  Go to top    Print page (opens in a new window)  Print page
 
Copyright © 1997-2009 Cyclacel Pharmaceuticals, Inc. All Rights Reserved  |  Site Map  |  Privacy  |  Disclaimer  |  Contact Us  |  Alerting Service